Ask about how you can participate in our open clinical trials and help pave the way for future advancements. Consider the possibilities and contribute to the health of your community.
| Trial | Activation status | Disease site | Disease type | Phase | Biomarker/pathology |
|---|---|---|---|---|---|
| TPX-005-01 (TRIDENT-1) | Open | All solid tumors | Locally advanced or metastatic solid tumor | 1/2 | ALK or ROS1 positive or NTRK1/2/3 rearrangements |
| DESTINY LUNG04 (AZ) | Open | Lung | Locally advanced or metastatic NSCLC | 3 | HER2 mutations in Exon 19 or 20 |
| LAWSON OCELOT | Open | Lung | Advanced NSCLC | 2 | EGFR activating mutation (excluding exon 20 insertions) |
| TAS6417-201: Resilient3 | Open | Lung | Advanced NSCLC | 2b | Exon 20 insertion and uncommon/single or compound epidermal growth factor receptor mutations |
| TAS6417-301: Resilient3 | Open | Lung | Locally advanced or metastatic non squamous NSCLC | 3 | EGFR exon 20 insertion |
| V940-002 | Open | Lung | Resected Stage II, IIIA, IIIB (N2) non-small cell lung cancer | 3 | |
| MK-2870-007 | Open | Lung | Non squamous and squamous metastatic NSCLC | 3 | PD-L1 TPS ≥50% |
| MK-2870-004 | Open | Lung | Advanced or metastatic non squamous NSCLC | 3 | EGFR mutations or ALK rearrangements or ROS1 rearrangements or RET rearrangements or BRAF V600E mutation or NTRK fusion or METx14 mutation |
| M18-868 | Open | Lung | EGFR wild-type advanced/metastatic NSCLC | Non squamous histology only | |
| SGNB6A-002 | Open | Lung | Non-small cell lung cancer with or without actionable genomic alterations | 3 | Non squamous histology only |
| JAVELIN MS100070-0119 | Open | Bladder | Locally advanced or metastatic urothelial cancer | 2 | |
| MK-3475-365 | Opening soon | Prostate | Metastatic castration resistant prostate cancer | 1/2 | Adenocarcinoma without small cell histology |
| REaCT-HOLD BMA (3CTN) | Open | Breast and prostate | Breast cancer and castrate resistant prostate cancer | 4 | |
| MA.40 (FINER) - CCTG | Open | Breast and prostate | Breast cancer and castrate resistant prostate cancer | 4 | HER2 low ER positive and/or PR positive |
| Pfizer C4391022 | Open | Breast | Advanced or metastastic breast cancer | 3 | HR positive and/or HER2 negative |
| Agendia Flex | Open | Breast | mammaprint testing for stage 1-3 ER positive/Her2 | Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing as standard of care | |
| DYNASTY-Breast02 (Duality) | Opening soon | Breast | Advanced or metastatic breast cancer | 3 | HER2 low ER positive and/or PR positive |
| SEAMARK (Pfizer) | Open | Colorectal | Metastatic colorectal cancer | 2 | BRAF V600E positive MSI-high MMR-deficient |
| TPX-005-01 (TRIDENT-1) | Open | All solid tumors | Locally advanced or metastatic solid tumor | 1/2 | ALK or ROS1 positive or NTRK1/2/3 rearrangements |
| MK-2140-007 | On hold by sponsor | Lymphoid | Diffuse large B-cell lymphoma | 2 | |
| Abbvie M20-621 | Open | Lymphoid | Diffuse large B-cell lymphoma | 3 | CD20 positive |
